Ephedrine (Protoalkaloid · Ma Huang · Banned Supplement · Sympathomimetic Informational)

Compound	Ephedrine (L-Ephedrine)
Chemical class	Alkaloid — Protoalkaloid (Phenylethylamine / phenylpropanolamine)
CAS	299-42-3
Primary source	Ephedra sinica (Ma Huang, green twigs), Ephedra species
Key applications	Controlled sympathomimetic bronchodilator; asthma, decongestant; banned dietary supplement; informational reference
Claim strength	High (as pharmaceutical); Informational only (supplement)
Typical form	Pharmaceutical tablet/injection; banned from dietary supplements (US FDA 2004); OTC restriction varies by market
Buy from Herbuno	Browse HerbIQ Compound Index →

Name origin: From Ephedra (the genus). Ephedrine is the primary alkaloid of Ephedra sinica (Ma Huang in TCM) — a phenylethylamine alkaloid with both amine and hydroxyl groups on the side chain (phenylpropanolamine class). It exists as the L-(−)-threo isomer in the plant and is pharmacologically distinct from its stereoisomers pseudoephedrine, norephedrine, and norpseudoephedrine. Traditional use: Ma Huang has been used in TCM for over 5,000 years — one of the oldest documented botanical medicines, referenced in the Shen Nong Ben Cao Jing (Classic of Herbal Medicine, ~100 CE). Traditional applications: asthma, bronchitis, fever, edema, and rhinitis. The discovery of ephedrine by Japanese pharmacologist Nagai Nagayoshi in 1885 and its pharmacological characterisation by Chen and Schmidt (1924) created modern sympathomimetic pharmacology. Regulatory history and current status: Ephedrine-containing dietary supplements (marketed for weight loss and athletic performance as “herbal fen-phen”, “Metabolife”, etc.) were associated with serious cardiovascular adverse events including heart attacks and strokes in the 1990s–early 2000s. The FDA banned ephedrine alkaloids from dietary supplements in 2004 — the first FDA ban of a dietary supplement ingredient. Ephedrine remains a Schedule III pseudoephedrine-precursor controlled substance in the US and similarly regulated in most markets. As a pharmaceutical: approved for nasal decongestant and bronchodilator uses in some markets but largely displaced by safer agents. Supplement status: Banned from dietary supplements in the US, EU, and most regulated markets.

---

Ephedrine — Pharmacological and Regulatory Context

Sympathomimetic mechanism — direct and indirect: Ephedrine is a mixed-acting sympathomimetic: (1) Direct agonism at α1, β1, and β2 adrenergic receptors; (2) Indirect displacement of norepinephrine from presynaptic vesicles (similar mechanism to amphetamine, but less potent). Effects: bronchodilation (β2), vasoconstriction/hypertension (α1), cardiac stimulation (β1), CNS stimulation. Tachyphylaxis develops with repeated dosing (norepinephrine depletion). Pharmacology well-characterised.

Weight loss and athletic performance (historical): Ephedrine + caffeine combinations were the most efficacious non-prescription weight loss agents before the 2004 FDA ban — multiple RCTs confirmed significant fat loss and lean mass preservation. The ephedrine-caffeine stack was also widely used in athletic performance for thermogenic and stimulant effects. These applications were banned due to cardiovascular adverse events at unregulated supplement doses. Claim strength: High (efficacy well-established); supplement use banned.

Asthma and bronchospasm (pharmaceutical): Ephedrine and pseudoephedrine were historically the primary bronchodilators before the development of selective β2 agonists (salbutamol, albuterol). Ephedrine still has some pharmaceutical uses in peri-operative hypotension management and as a nasal decongestant in some markets. Pharmaceutical evidence: High.

---

Frequently Asked Questions — Ephedrine

Why was ephedrine banned from supplements but not pharmaceuticals?
The 2004 FDA ban applied specifically to ephedrine alkaloids in dietary supplements marketed for weight loss and athletic performance. Pharmaceutical ephedrine (as a regulated drug with defined dosing and indication) was not banned. The distinction reflects the unregulated dosing, combination products (with caffeine and other stimulants), and aggressive marketing in the supplement industry that produced the adverse event profile leading to the ban — not a finding that pharmaceutical ephedrine use is unsafe at controlled clinical doses.

What is the difference between ephedrine and pseudoephedrine?
Ephedrine (1R,2S configuration) and pseudoephedrine (1S,2S) are stereoisomers. Ephedrine is a more potent CNS stimulant and bronchodilator; pseudoephedrine is a better nasal decongestant with less CNS stimulation (due to lower CNS penetration). Pseudoephedrine is sold OTC as Sudafed and is regulated as a meth precursor under Combat Methamphetamine Epidemic Act (CMEA); ephedrine is a Schedule III controlled substance precursor in the US.

Is Ma Huang (Ephedra) still available as a herbal supplement?
Ma Huang (Ephedra sinica herb) is banned in dietary supplements in the US if it contains ephedrine alkaloids. The FDA ban covers the alkaloids, not necessarily the whole herb, but extracting and using Ephedra herb in a supplement product containing ephedrine alkaloids violates the 2004 rule. Ephedra tea is sold in some markets as a non-supplement beverage. Traditional TCM practitioners may still prescribe Ma Huang in compound formulations under appropriate TCM regulatory frameworks.

Are there safe natural alternatives to ephedrine for thermogenic formulations?
Post-ephedrine ban, the supplement industry has adopted: synephrine (bitter orange, β3 adrenergic agonist, less cardiovascular risk; built in SM10); caffeine (well-characterised thermogenic); capsaicin/capsinoids (TRPV1 thermogenic); green tea EGCG + caffeine (synergistic thermogenic). None matches the efficacy of ephedrine+caffeine for fat loss in RCTs, but the safety profile of these alternatives is substantially better.

Related compounds: Pseudoephedrine, Synephrine, Capsaicin, Hordenine

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery